How could the PDUFA date for Anaphylm affect the Center for Drug Evaluation and Research?
CDER faces a critical March 2027 deadline for Anaphylm drug review The resubmission of Anaphylm's New Drug Application has established a Prescription Drug User Fee Act (PDUFA) date of March 16, 2027. This date marks the intended deadline for the FDA's review of the drug application, a process managed by the Center for Drug Evaluation and Research. The review is tied to Eton's exclusive U.S. commercialization rights, meaning the division must complete its evaluation by this date to allow for the potential launch of the epinephrine sublingual film candidate.
- Effect
- Mixed
- How direct
- Brind's reasoning
- When
- Within weeks
- The story
- Still developing
How it reaches Center for Drug Evaluation and Research
-
Eton received exclusive U.S. commercialization rights for Anaphylm, which was tied to FDA acceptance. The FDA accepted the resubmitted New Drug Application as a Class 2 response, setting the Anaphylm PDUFA Date for March 16, 2027. Eton also received a $10 million upfront payment for these exclusive U.S. commercialization rights.
The full event1independent outlet -
As a formal division of the FDA, the Center for Drug Evaluation and Research is responsible for managing the drug evaluation process, including the review of New Drug Applications like Anaphylm's.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Drug Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Eton received exclusive U.S. commercialization rights for Anaphylm, tied to FDA acceptance.fool.com
- The Anaphylm PDUFA Date is March 16, 2027, following the FDA's acceptance of the resubmitted New Drug Application as a Class 2 response.fool.com
- The company is ramping up for the US launch of ANNAFILM following FDA approval.fool.com
Why it matters
The PDUFA date represents a critical operational milestone for the Center for Drug Evaluation and Research. Meeting this deadline is essential for the regulatory process to conclude, allowing the potential commercialization of Anaphylm in the United States. Failure to meet this deadline or delays in the review process could significantly impact the timeline for the drug's availability and Eton's commercial strategy.
This process is part of the broader regulatory framework where the FDA, through its specialized divisions like CDER, manages the approval of new pharmaceutical candidates. The successful review of Anaphylm is directly linked to Eton's licensing agreement and the company's focus on expanding its global regulatory filings, including those for Health Canada and the European Union.
What we don't know yet
- What specific conditions must be satisfied for the FDA to grant approval of Anaphylm?
- How will the FDA prioritize the review of Anaphylm against other pending applications?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comYesterday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.